Murcia Puts Out to Tender for €500,000 the Works of the Clinical Trials Unit in Arrixaca

Murcia advances in pharmacology. The Government of the community is putting out to tender the works to implement a clinical trials unit at the Virgen de la Arrixaca University Clinical Hospital for half a million euros, according to the profile of the contractor in the region.

Specifically, it involves the launch in the Murcia Hospital of a clinical trial unit in the early phases of medicines. The execution period of the contest is six months.

“The Virgen de la Arrixaca hospital is patient-oriented in both its healthcare, teaching, and research aspects, seeking to improve its services; Healthcare activity is essential to satisfy health needs, and teaching and research activities are essential tools for its achievement,” according to the information in the contract specifications.

Read more about the new clinical trials unit that will be built in Murcia and find the latest financial news of the day with our companion app Born2Invest.

Murcia establishes an execution period of six months for the clinical trials unit

The creation of the clinical trials unit arose to enhance and support all clinical research carried out within the framework of an early phase clinical trial (phase I-II). It is designed to provide maximum scientific and technical support in the context of high-quality care, teaching, and experimental research.

The objective is to develop this type of early clinical research with drugs (first administration in humans, dose search, safety, tolerance) and provide patients included in the trial with new treatment opportunities with quality care.

At the Virgen de la Arrixaca University Clinical Hospital, the Murcia Government put out to tender last July the supply, installation, and start-up of the planning system for the radiation oncology service. The planning system is key in the radiotherapy treatment of oncological patients for the simulation, planning, and calculation of monitor units of external radiotherapy treatments (linear accelerator treatments).

The main external planning system for the Virgen de la Arrixaca since 2002 has been Pinnacle, from the Philips company. This is equipment that concluded its useful life at the end of 2020.

The contract includes the supply, under a lease without an option to purchase, of a platform for planning all external radiotherapy treatments in any of the five linear accelerators of the radiotherapy oncology service.

__

(Featured image by AG-Pics via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.